原发性肝癌中医专病队列长期随访结果OA
Long-Term Follow-Up Outcomes of a Traditional Chinese Medicine Disease-Specific Cohort for Primary Liver Cancer
目的 更新已发表的原发性肝癌中医专病队列长期随访数据,进一步评估以国医大师周岱翰学术思想为指导的中医辨证施治对肝癌患者的远期疗效.方法 本研究为回顾性队列研究,纳入2020年9月至2022年12月周岱翰教授经治的原发性肝癌患者223例.根据是否接受根治性治疗分为根治性亚队列(119例)和不可根治亚队列(101例),再依据是否接受规范(及时、规律)的中医辨证施治分为暴露组与非暴露组.主要观察指标为至复发时间(time to recurrence,TTR)和总生存时间(overall survival,OS),采用倾向性评分匹配(propensity score matching,PSM)控制混杂偏倚,Kaplan-Meier法绘制生存曲线,Log-rank检验比较组间差异,Cox回归计算风险比(hazard ratio,HR).本次分析随访截止至2025年10月18日,更新了5年、7年、10年长期生存数据.结果 在根治性亚队列中(PSM后每组52例),暴露组中位TTR显著长于非暴露组(51.2个月 vs 10.5个月,HR=0.30,95%CI:0.19~0.48,P<0.001),7年、10年无复发率分别为37.5%vs 5.7%与37.5%vs 3.9%;暴露组中位OS尚未达到,非暴露组为65.0个月(HR=0.41,95%CI:0.22~0.79,P<0.010),10年生存率分别为66.1%vs 39.6%.在不可根治亚队列中,暴露组中位OS显著长于非暴露组(22.4个月 vs 9.7个月,HR=0.57,95%CI:0.36~0.89,P=0.020),5年生存率为17.6%vs 0.多因素Cox回归分析显示,中医辨证施治是TTR和OS的独立保护因素.结论 以周岱翰教授"带瘤生存"学术思想为指导的中医辨证施治可显著延缓肝癌术后复发、延长不可根治患者生存时间,使患者获得长期生存获益.
Objective To update long-term outcomes from a previously reported traditional Chinese medicine(TCM)disease-specific cohort for primary liver cancer,and to evaluate the efficacy of TCM syndrome-based treatment guided by Chinese medicine master Professor Zhou Daihan in patients with liver cancer.Methods This retrospective cohort study included 223 primary liver cancer patients treated by Professor Zhou from September 2020 and December 2022.Patients were divided into a curative subcohort(119 cases)and a non-curative subcohort(101 cases),and were further divided into exposed and non-exposed group according to their receipt of standardized(timely and regular)TCM syndrome-based treatment.The primary endpoints were time to recurrence(TTR)and overall survival(OS).Propensity score matching(PSM)was used to minimize confounding.Survival curves were estimated using the Kaplan-Meier method,between-group differences were assessed with the log-rank test,and hazard ratios(HRs)were calculated via Cox regression.The follow-up was updated as of October 18,2025,providing new 5-year,7-year,and 10-year survival data.Results In the curative subcohort(52 patients per group after PSM),the exposed group had a significantly longer median TTR than the non-exposed group(51.2 months vs 10.5 months,HR=0.30,95%CI:0.19~0.48,P<0.001).The 7-year and 10-year recurrence-free survival rates were 37.5%vs 5.7%and 37.5%vs 3.9%,respectively.The median OS was not reached in the exposed group versus 65.0 months in the non-exposed group(HR=0.41,95%CI:0.22~0.79,P<0.010),with 10-year OS rates of 66.1%and 39.6%,respectively.In the non-curative subcohort,median OS was significantly longer in the exposed group than in the non-exposed group(22.4 months vs 9.7 months,HR=0.57,95%CI:0.36~0.89,P=0.020),and the 5-year OS rate was 17.6%in the exposed group versus 0 in the non-exposed group.Multivariate Cox regression identified TCM syndrome-based treatment as an independent protective factor for both TTR and OS.Conclusion TCM syndrome-based treatment,grounded in Professor Zhou Daihan's"survival with tumor"philosophy,can significantly delay postoperative recurrence,prolong survival in patients with unresectable disease,and achieve long-term survival benefits.
陈虹宇;周瑞生;唐莹;吴岱琳;甄宏德;庄振杰;高天琦;潘艳丽;周岱翰
广州中医药大学深圳医院(福田)肿瘤中心,广东 深圳 518034||深圳市中医肿瘤医学中心,广东 深圳 518034深圳市中医肿瘤医学中心,广东 深圳 518034||广州中医药大学第一附属医院,广东 广州 510405广州中医药大学中医肿瘤研究所,广东 广州 510405广州中医药大学第一临床医学院,广东 广州 510405浙江省肿瘤医院中医科,浙江 杭州 310022广东省中医院肿瘤科,广东 广州 511400广州中医药大学第一附属医院血液科,广东 广州 510405固生堂中医连锁集团门诊部,广东 广州 518112深圳市中医肿瘤医学中心,广东 深圳 518034||广州中医药大学第一附属医院,广东 广州 510405||广州中医药大学中医肿瘤研究所,广东 广州 510405
医药卫生
原发性肝癌中医辨证施治队列研究长期随访
primary liver cancertraditional Chinese medicine syndrome-based treatmentcohort studylong-term follow-up
《中医肿瘤学杂志》 2026 (4)
33-41,9
国家自然科学基金(编号:82575167)深圳市"医疗卫生三名工程"项目(编号:SZZYSM202311011)广州市卫健委国医大师传承创新工程项目(编号:穗卫中医[2025]2号)广州地区中西医协同临床重大创新技术建设项目广州中医药大学第一附属医院2025年周岱翰国医大师学术思想传承项目(编号:08003007015).
评论